Qiming Venture Partners

Few firms have shaped Chinese healthcare venture capital as decisively as Qiming Venture Partners. Founded in Shanghai in 2006 by Duane Kuang and Gary Rieschel, the firm has spent nearly two decades building one of the largest dedicated healthcare practices in Asia, with more than one hundred portfolio companies in diagnostics, R&D, devices, and services. For physician-founders building AI tools, Qiming represents something rare: a partner with the operating depth to navigate Chinese hospital procurement, the regulatory patience to wait through NMPA review cycles, and the cross-border reach to coordinate parallel commercialization in the United States through Qiming Venture Partners USA, established in 2017 as a separate biotech-focused vehicle.

Qiming’s investment thesis treats healthcare as a long-cycle, science-led category rather than an adjacent software market. The firm invests across Series A through Series C in biotech, medical devices and MedTech, and digital health, writing checks in the five-to-twenty-five-million-dollar range. Across eleven US dollar funds and seven RMB funds totaling approximately $9.5 billion, Qiming has been willing to underwrite both clinical and capital risk in categories where peers retreat: novel diagnostics platforms, surgical devices requiring multi-site evidence, and translational therapeutics with multi-year regulatory paths. AI is treated as a substrate that strengthens diagnostic accuracy, drug discovery, and operational throughput, not as a standalone vertical. The firm’s preference is for teams whose technical thesis is grounded in clinical workflow or molecular biology rather than thin software wrappers around third-party models. Founders should expect detailed technical diligence, references with practicing clinicians, and a willingness to lead pricing rather than follow market consensus.

The healthcare portfolio offers a useful map of what Qiming actually backs. Zai Lab, the in-licensing biotech that listed on Nasdaq and the Hong Kong Exchange, is among the firm’s most prominent therapeutics outcomes. CanSino Biologics, the vaccine developer, demonstrates Qiming’s willingness to back complex biologics through approval. AmoyDx in molecular diagnostics and Berry Genomics in genomic sequencing reflect the firm’s diagnostics franchise. Gan & Lee Pharmaceuticals on the pharma side and APT Medical and Sanyou Medical in devices round out a portfolio that spans the full clinical commercialization spectrum. For physician-AI founders, the relevance is that Qiming is comfortable underwriting companies whose value depends on regulatory milestones, not just user growth.

Stage and check size align with Qiming’s posture as a price-leading institutional investor. The five-to-twenty-five-million-dollar band fits a clean Series A in a clinical-AI company with prospective evidence in hand, or a follow-on at Series B or C as commercial traction builds. The firm typically takes lead positions, prices rounds with conviction, and reserves meaningful follow-on capital, having scaled multiple companies from early clinical stage through public listing. Founders raising bridge rounds or party rounds without a clear lead are unlikely to find Qiming a natural fit. Founders raising a defining round with a multi-year capital plan, a credible regulatory strategy, and ambition to operate across both Chinese and global markets will find a partner that has done this many times before.

Decision-making sits with a senior investment team that has been together for years. Duane Kuang, Founder and Managing Partner, anchors the firm’s strategic posture. Nisa Leung, who joined in 2006 and rose to managing partner, leads much of the healthcare practice and is one of the most influential healthcare investors in Asia. Kan Chen, a Partner with deep pharmaceutical R&D background, co-leads healthcare. The Qiming USA platform operates as a separate biotech-focused vehicle for early-stage opportunities. Investment committees place weight on clinical and scientific defensibility, regulatory path, and management depth.

The most reliable warm-intro paths are through existing portfolio CEOs, especially in adjacent diagnostics or device companies, and through clinical advisors at the major Beijing and Shanghai academic medical centers Qiming knows well. Strategic partners at multinational pharma and device firms with Asia operations frequently route deals to the team. Co-investors from prior rounds, including international healthcare-specialist funds, also serve as effective routes. Cold inbound through generic forms is the slowest path; the firm responds materially better to introductions from people who have done diligence on the technology themselves and can vouch for the founding team.

Founders should approach Qiming when they have prospective clinical data or a credible regulatory plan, a defined commercialization path in at least one major market, and a willingness to operate across the US-China axis rather than treat one geography as an afterthought. Pre-clinical stories without a clinical advisor bench, or thin-data digital health pitches, will not survive technical diligence. The firm rewards founders who arrive with specifics on hospital adoption, reimbursement strategy, and competitive moat, and who can articulate why their molecular or algorithmic approach holds up under independent review.